Atopic dermatitis - the review
Authors:
- Joanna WronaJWJoanna Wrona
- Aleksandra KaźmierczykAKAleksandra Kaźmierczyk
- Jędrzej KęsikJKJędrzej Kęsik
- Daria MadyckaDMDaria Madycka
- Kacper MichtaKMKacper Michta
- Małgorzata SłabońMSMałgorzata Słaboń
- Aleksandra WójcikAWAleksandra Wójcik
- Karol StępniakKSKarol Stępniak
- Wiktor TelegaWTWiktor Telega
- Kinga WnuczekKWKinga Wnuczek
Open Access
- 3 January 2025
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 37, 56851
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by a disrupted epidermal barrier, immune dysregulation, and genetic predisposition. Affecting individuals across all age groups, AD presents with recurrent flare-ups and varying clinical patterns depending on age. The pathophysiology involves key elements such as loss-of-function mutations in the filaggrin (FLG) gene, overproduction of cytokines like IL-4 and IL-13, and skin colonization by Staphylococcus aureus. Management strategies include patient education, topical therapies (e.g., corticosteroids, calcineurin inhibitors, crisaborole, and tapinarof), systemic treatments like dupilumab and methotrexate, and phototherapy for refractory cases. Preventive measures, including breastfeeding and probiotic supplementation, offer limited benefits, emphasizing the need for individualized approaches. Innovative therapies and further research into AD pathogenesis hold promise for more effective disease control and improved quality of life for patients.Keywords
This publication has 40 references indexed in Scilit:
- Patient-reported burden in adults with atopic dermatitis: an international qualitative studyArchives of Dermatological Research, 2024
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJournal of the American Academy of Dermatology, 2024
- Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic DermatitisCurrent Allergy and Asthma Reports, 2024
- Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAdvances in Therapy, 2024
- Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendationsAnnals of Allergy, Asthma & Immunology, 2023
- Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric SettingPediatric Drugs, 2022
- An Update on the Pathophysiology of Atopic DermatitisDermatologic Clinics, 2017
- The Long-Term Course of Atopic DermatitisDermatologic Clinics, 2017
- Public Health Burden and Epidemiology of Atopic DermatitisDermatologic Clinics, 2017
- Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitisJournal of Allergy and Clinical Immunology, 2016